Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Helius Medical Technologies (NASDAQ:HSDT) and Corbus Pharmaceuticals (NASDAQ:CRBP).
Helius Medical Technologies (HSDT)
In a report released yesterday, Sean Lavin from BTIG maintained a Hold rating on Helius Medical Technologies. The company’s shares closed yesterday at $10.16.
Lavin observed:
“Monday morning, Helius announced its PoNS device received regulatory clearance from Health Canada. This milestone allows PoNS Therapy to be commercialized in Canada; the therapy will be delivered at branded Heuro Canada neuroplasticity centers. Two centers are expected to be operational by the end of 2018 and are slated to start treating patients in 1Q19. The timing of this approval came in line with management’s expectations and ahead of our anticipated timeline. We await further details regarding Canadian commercialization on the company’s November earnings call, but see this as an accomplishment that increases our confidence around FDA clearance.”
According to TipRanks.com, Lavin is a 5-star analyst with an average return of 11.7% and a 58.8% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings Inc, Tactile Systems Technology, and Obalon Therapeutics Inc.
The word on The Street in general, suggests a Hold analyst consensus rating for Helius Medical Technologies.
See today’s analyst top recommended stocks >>
Corbus Pharmaceuticals (CRBP)
In a report released yesterday, Kumaraguru Raja from Brookline Capital Markets maintained a Buy rating on Corbus Pharmaceuticals, with a price target of $25. The company’s shares closed yesterday at $7.18.
According to TipRanks.com, Raja is a 1-star analyst with an average return of -4.4% and a 52.0% success rate. Raja covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics Ltd, Acer Therapeutics Inc, and Tonix Pharma.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Corbus Pharmaceuticals with a $29.33 average price target, representing a 308.5% upside. In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $36 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
